About Histone-lysine N-methyltransferase SETD7
Histone-lysine N-methyltransferase SETD7 (SETD7) is a protein
from Homo sapiens identified by UniProt accession
Q8WTS6, 366 residues long.
MolForge cross-references it against 0 known binders and
145 disease associations.
Target properties
| Protein name | Histone-lysine N-methyltransferase SETD7 |
| UniProt accession | Q8WTS6 |
| Gene | SETD7 |
| Organism | Homo sapiens |
| Length | 366 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (145)
Diseases linked to this target (Open Targets).
- lycopene measurement · score 0.29
- breast adenocarcinoma · score 0.24
- neoplasm · score 0.11
- hepatocellular carcinoma · score 0.10
- cancer · score 0.10
- breast cancer · score 0.09
- acute myeloid leukemia · score 0.08
- papillary thyroid carcinoma · score 0.08
- nonpapillary renal cell carcinoma · score 0.07
- lung adenocarcinoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8WTS6-F1 | alphafold | PREDICTED | 94.42 | — |
Amino-acid sequence (366 residues)
MDSDDEMVEE AVEGHLDDDG LPHGFCTVTY SSTDRFEGNF VHGEKNGRGK FFFFDGSTLE GYYVDDALQG QGVYTYEDGG VLQGTYVDGE LNGPAQEYDT DGRLIFKGQY KDNIRHGVCW IYYPDGGSLV GEVNEDGEMT GEKIAYVYPD ERTALYGKFI DGEMIEGKLA TLMSTEEGRP HFELMPGNSV YHFDKSTSSC ISTNALLPDP YESERVYVAE SLISSAGEGL FSKVAVGPNT VMSFYNGVRI THQEVDSRDW ALNGNTLSLD EETVIDVPEP YNHVSKYCAS LGHKANHSFT PNCIYDMFVH PRFGPIKCIR TLRAVEADEE LTVAYGYDHS PPGKSGPEAP EWYQVELKAF QATQQK
Explore Histone-lysine N-methyltransferase SETD7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets